These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Identification of Chiem K; Nogales A; Lorenzo M; Morales Vasquez D; Xiang Y; Gupta YK; Blasco R; de la Torre JC; Martínez-Sobrido L Microbiol Spectr; 2023 Aug; 11(4):e0474522. PubMed ID: 37278625 [TBL] [Abstract][Full Text] [Related]
6. Potential Inhibitors of Monkeypox Virus Revealed by Molecular Modeling Approach to Viral DNA Topoisomerase I. Hu X; An S; Chu J; Liang B; Liao Y; Jiang J; Lin Y; Ye L; Liang H Molecules; 2023 Feb; 28(3):. PubMed ID: 36771105 [TBL] [Abstract][Full Text] [Related]
7. Antivirals against monkeypox infections. Chiem K; Nogales A; Lorenzo M; Vasquez DM; Xiang Y; Gupta YK; Blasco R; de la Torre JC; Mart Nez-Sobrido L bioRxiv; 2023 Apr; ():. PubMed ID: 37131608 [TBL] [Abstract][Full Text] [Related]
8. Supervised screening of Tecovirimat-like compounds as potential inhibitors for the monkeypox virus E8L protein. Mehmood A; Nawab S; Jia G; Kaushik AC; Wei DQ J Biomol Struct Dyn; 2023 Aug; ():1-14. PubMed ID: 37561169 [TBL] [Abstract][Full Text] [Related]
9. Screening of potential inhibitors against structural proteins from Monkeypox and related viruses of Kaur M; Sharma A; Kaur H; Singh M; Devi B; Naresh Raj AR; Sood V; Pandey A; Gartia J; Kumar R; Suresh Babu AR; Singh G; Barnwal RP J Biomol Struct Dyn; 2023 Sep; ():1-16. PubMed ID: 37776002 [TBL] [Abstract][Full Text] [Related]
10. Fragment-Based Approaches Identified Tecovirimat-Competitive Novel Drug Candidate for Targeting the F13 Protein of the Monkeypox Virus. Ali Y; Imtiaz H; Tahir MM; Gul F; Saddozai UAK; Ur Rehman A; Ren ZG; Khattak S; Ji XY Viruses; 2023 Feb; 15(2):. PubMed ID: 36851785 [TBL] [Abstract][Full Text] [Related]
12. Proteome-Based Investigation Identified Potential Drug Repurposable Small Molecules Against Monkeypox Disease. Bhattacharjee A; Ahammad I; Chowdhury ZM; Das KC; Keya CA; Salimullah M Mol Biotechnol; 2024 Apr; 66(4):626-640. PubMed ID: 36357534 [TBL] [Abstract][Full Text] [Related]
13. In vitro susceptibility of eighteen clinical isolates of human monkeypox virus to tecovirimat. Nunes DDS; Higa LM; Oliveira RL; da Costa LC; Bomfim LM; Gonçalves CCA; Mariani D; Hruby DE; Voloch CM; Castiñeiras TMPP; Tanuri A; Damaso CR Mem Inst Oswaldo Cruz; 2023; 118():e230056. PubMed ID: 37436275 [TBL] [Abstract][Full Text] [Related]
14. Machine learning and classical MD simulation to identify inhibitors against the P37 envelope protein of monkeypox virus. Rout M; Dey S; Mishra S; Panda S; Singh MK; Sinha R; Dehury B; Pati S J Biomol Struct Dyn; 2024 May; 42(8):3935-3948. PubMed ID: 37221882 [TBL] [Abstract][Full Text] [Related]
15. Computational Repurposing of Mitoxantrone-Related Structures against Monkeypox Virus: A Molecular Docking and 3D Pharmacophore Study. Preet G; Oluwabusola ET; Milne BF; Ebel R; Jaspars M Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430762 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and Efficacy of a Potential Smallpox Therapeutic, Brincidofovir, in a Lethal Monkeypox Virus Animal Model. Hutson CL; Kondas AV; Mauldin MR; Doty JB; Grossi IM; Morgan CN; Ostergaard SD; Hughes CM; Nakazawa Y; Kling C; Martin BE; Ellison JA; Carroll DS; Gallardo-Romero NF; Olson VA mSphere; 2021 Feb; 6(1):. PubMed ID: 33536322 [TBL] [Abstract][Full Text] [Related]
17. Potential therapeutic targets for Mpox: the evidence to date. Byrareddy SN; Sharma K; Sachdev S; Reddy AS; Acharya A; Klaustermeier KM; Lorson CL; Singh K Expert Opin Ther Targets; 2023; 27(6):419-431. PubMed ID: 37368464 [TBL] [Abstract][Full Text] [Related]
18. Tecovirimat Resistance in Mpox Patients, United States, 2022-2023. Smith TG; Gigante CM; Wynn NT; Matheny A; Davidson W; Yang Y; Condori RE; O'Connell K; Kovar L; Williams TL; Yu YC; Petersen BW; Baird N; Lowe D; Li Y; Satheshkumar PS; Hutson CL Emerg Infect Dis; 2023 Dec; 29(12):2426-2432. PubMed ID: 37856204 [TBL] [Abstract][Full Text] [Related]
19. Pharmacoinformatics-based identification of potential bioactive compounds against Ebola virus protein VP24. Kwofie SK; Broni E; Teye J; Quansah E; Issah I; Wilson MD; Miller WA; Tiburu EK; Bonney JHK Comput Biol Med; 2019 Oct; 113():103414. PubMed ID: 31536833 [TBL] [Abstract][Full Text] [Related]
20. Identification of IMP Dehydrogenase as a Potential Target for Anti-Mpox Virus Agents. Hishiki T; Morita T; Akazawa D; Ohashi H; Park ES; Kataoka M; Mifune J; Shionoya K; Tsuchimoto K; Ojima S; Azam AH; Nakajima S; Kawahara M; Yoshikawa T; Shimojima M; Kiga K; Maeda K; Suzuki T; Ebihara H; Takahashi Y; Watashi K Microbiol Spectr; 2023 Aug; 11(4):e0056623. PubMed ID: 37409948 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]